Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

 SHIChang-cheng ¹ , TIANGang ² , LOUJiang ¹ , WUJing ³

1. Department of Pharmacy, the First People's Hospital of Hangzhou, Hangzhou 310006, China;
2. Zhejiang Chinese Medical University, Hangzhou 310053, China;
3. Department of Pharmacy, Hangzhou Obstetrics & Gynecology Hospital, Hangzhou 310008, China;

Corresponding?author：

Keywords：

Selective serotonin reuptake inhibitors; Parkinson's disease; Depression; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20150073

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in the treatment of Parkinson's disease patients with depression. Methods The Cochrane Library (Issue 5, 2014), PubMed, EMbase, CNKI, VIP and WanFang Data databases were searched from inception to May 2014 for randomized controlled trials (RCTs) investigating the efficacy and safety of SSRIs for Parkinson's disease patients with depression. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. Results A total of 12 RCTs were included. The results of meta-analysis showed that the efficacy of SSRIs was better than placebo (RR=2.18, 95%CI 1.60 to 2.97, P<0.000 01) and the dropouts rates of SSRIs were higher than placebo (OR=3.02, 95%CI 1.04 to 8.79, P=0.04). However, the incidence rate of adverse events between the SSRIs group and the placebo group was not statistically different. Conclusion Current evidence indicates that SSRIs are effective for the Parkinson's disease patients with depression. Because of the limitation of quantity and quality of included studies, large-scale multi-center RCTs are required to confirm these findings.

Citation： SHIChang-cheng, TIANGang, LOUJiang, WUJing. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2015, 15(4): 439-444. doi: 10.7507/1672-2531.20150073 Copy

1.	Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 2008, 23(2):183-189.
2.	Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson's disease:systematic review and meta-analysis. J Psychopharmacol, 2013, 27(5):417-423.
3.	劉治軍, 趙明, 陳乃宏, 等. 4種臨床常見選擇性5-羥色胺再攝取抑制劑對5-羥色胺轉運體的抑制作用比較. 中國藥學雜志, 2008, 43(15):1149-1152.
4.	Chen P, Kales HC, Weintraub D, et al. Antidepressant treatment of veterans with Parkinson's disease and depression:analysis of a national sample. J Geriatr Psychiatry Neurol, 2007, 20(3):161-165.
5.	de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson's disease. Neurology, 1997, 48(5):1277-1281.
6.	全國椎體系疾病討論會. 帕金森病及帕金森綜合癥的診斷標準和鑒別診斷. 中華神經精神科雜志, 1985, 18(4):256.
7.	鄧可剛. 循證醫學證據的檢索步驟與檢索系統的選擇. 中國循證醫學雜志, 2004, 4(9):634-637.
8.	Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:Assessing risk of bias in included studies. In:Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
9.	陳娟, 李強. 氟西汀治療帕金森病抑郁患者的療效觀察. 中國實用神經疾病雜志, 2009, 12(15):28-29.
10.	Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in parkinson's disease:a double-blind, randomized, placebo-controlled study. Mov Disord, 2008, 23(6):850-857.
11.	馮傳學, 王啟盛. 氟西汀對帕金森病伴抑郁及神經癥狀的影響. 中國現代藥物應用, 2008, 2(20):55-56.
12.	Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry, 2003, 18(6):552-554.
13.	林勇, 丁雪萍, 周勇. 舍曲林治療帕金森病合并抑郁的療效分析. 精神醫學雜志, 2007, 20(6):389-390.
14.	林智君, 鄭選梅. 百憂解治療帕金森病伴抑郁的臨床研究. 中國實用醫藥, 2010, 5(12):80-81.
15.	劉晶晶, 王恩銘, 江振華, 等. 帕羅西汀治療帕金森病抑郁患者的療效. 實用臨床醫學, 2013, 14(1):19-25.
16.	馬海蓉. 帕羅西汀治療帕金森病伴抑郁的療效評價. 中國現代應用藥學雜志, 2006, 23(4):344-345.
17.	孟新玲, 房江山, 劉遠新, 等. 鹽酸帕羅西汀片對帕金森病患者合并抑郁和焦慮癥狀的臨床療效. 中國臨床藥理學雜志, 2013, 29(6):403-405.
18.	Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, 72(10):886-892.
19.	Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, 78(16):1229-1236.
20.	張春穎, 林傳水, 賀國鳳. 帕羅西汀對帕金森病伴抑郁及神經癥狀的影響. 神經疾病與精神衛生, 2005, 5(3):208-209.

1. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 2008, 23(2):183-189.
2. Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson's disease:systematic review and meta-analysis. J Psychopharmacol, 2013, 27(5):417-423.
3. 劉治軍, 趙明, 陳乃宏, 等. 4種臨床常見選擇性5-羥色胺再攝取抑制劑對5-羥色胺轉運體的抑制作用比較. 中國藥學雜志, 2008, 43(15):1149-1152.
4. Chen P, Kales HC, Weintraub D, et al. Antidepressant treatment of veterans with Parkinson's disease and depression:analysis of a national sample. J Geriatr Psychiatry Neurol, 2007, 20(3):161-165.
5. de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson's disease. Neurology, 1997, 48(5):1277-1281.
6. 全國椎體系疾病討論會. 帕金森病及帕金森綜合癥的診斷標準和鑒別診斷. 中華神經精神科雜志, 1985, 18(4):256.
7. 鄧可剛. 循證醫學證據的檢索步驟與檢索系統的選擇. 中國循證醫學雜志, 2004, 4(9):634-637.
8. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:Assessing risk of bias in included studies. In:Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
9. 陳娟, 李強. 氟西汀治療帕金森病抑郁患者的療效觀察. 中國實用神經疾病雜志, 2009, 12(15):28-29.
10. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in parkinson's disease:a double-blind, randomized, placebo-controlled study. Mov Disord, 2008, 23(6):850-857.
11. 馮傳學, 王啟盛. 氟西汀對帕金森病伴抑郁及神經癥狀的影響. 中國現代藥物應用, 2008, 2(20):55-56.
12. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry, 2003, 18(6):552-554.
13. 林勇, 丁雪萍, 周勇. 舍曲林治療帕金森病合并抑郁的療效分析. 精神醫學雜志, 2007, 20(6):389-390.
14. 林智君, 鄭選梅. 百憂解治療帕金森病伴抑郁的臨床研究. 中國實用醫藥, 2010, 5(12):80-81.
15. 劉晶晶, 王恩銘, 江振華, 等. 帕羅西汀治療帕金森病抑郁患者的療效. 實用臨床醫學, 2013, 14(1):19-25.
16. 馬海蓉. 帕羅西汀治療帕金森病伴抑郁的療效評價. 中國現代應用藥學雜志, 2006, 23(4):344-345.
17. 孟新玲, 房江山, 劉遠新, 等. 鹽酸帕羅西汀片對帕金森病患者合并抑郁和焦慮癥狀的臨床療效. 中國臨床藥理學雜志, 2013, 29(6):403-405.
18. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, 72(10):886-892.
19. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, 78(16):1229-1236.
20. 張春穎, 林傳水, 賀國鳳. 帕羅西汀對帕金森病伴抑郁及神經癥狀的影響. 神經疾病與精神衛生, 2005, 5(3):208-209.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content